EuroPCR 2018: Study compares drug-coated balloons in patients with arterial in-stent restenosis
At this year’s annual EuroPCR meeting, Boston Scientific (NYSE:BSXtouted results from the first trial to compare two drug-coated balloons with different drug formulations – Boston Scientific’s Agent paclitaxel-coated PTCA device and B. Braun’s SeQuent Please balloon.
The 125-patient study evaluated the balloons in patients with in-stent restenosis of a lesion previously treated with a drug-eluting stent or drug-coated balloon.
Get the full story at our sister site, Drug Delivery Business News.
The post EuroPCR 2018: Study compares drug-coated balloons in patients with arterial in-stent restenosis appeared first...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Amaranth Medical B. Braun Boston Scientific Source Type: news
Many Prescriptions for Newer, More Expensive Antiplatelet Agents Go Unfilled Many Prescriptions for Newer, More Expensive Antiplatelet Agents Go Unfilled
Prescriptions for the P2Y12 inhibitors prasugrel hydrochloride and ticagrelor hydrochloride after percutaneous coronary intervention (PCI) are outpacing those for clopidogrel, but many patients are not filling those prescriptions, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Reporting outcomes of PCI may not improve care
(Reuters Health) - Public reporting of outcomes for percutaneous coronary intervention (PCI) was supposed to improve quality, but some doctors say it hasn't delivered on the goal of enhancing patient care. (Source: Reuters: Health)
Source: Reuters: Health - May 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Teleflex launches TrapLiner cath in the EU
Teleflex (NYSE:TFX) said yesterday it launched the TrapLiner catheter, designed for use in vascular procedures, in Europe.
The Wayne, Penn.-based company said that its TrapLiner cath is similar in design to its GuideLiner V3 cath but also features an integrated balloon for trapping standard 0.014″ guidewires within a guide catheter.
The newly launched TrapLiner catheter is designed to operate as an alternative method to the trapping technique which requires the use of a PTCA balloon to exchange an existing over-the-wire catheter while maintaining guidewire position, Teleflex said.
The catheter is intended for use al...
Source: Mass Device - May 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Catheters Vascular Teleflex Source Type: news
Doctors May Avoid Performing PCI Due to Public Reporting
WEDNESDAY, May 16, 2018 -- Current percutaneous coronary intervention (PCI) public reporting programs could have negative effects, with physicians avoiding PCI in high-risk patients, according to a study published online May 9 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2018 Category: Pharmaceuticals Source Type: news
How do public 'report cards' affect physicians' treatment decisions?
(Beth Israel Deaconess Medical Center) Researchers from the Smith Center for Outcomes Research in Cardiology at Beth Israel Deaconess Medical Center (BIDMC) provide a closer look at physicians' knowledge, attitudes and beliefs about public reporting on percutaneous coronary intervention (PCI). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 10, 2018 Category: International Medicine & Public Health Source Type: news
Zoll Medical leads debt round for TherOx
TherOx said today it completed a new round of debt financing led by Asahi Kasei (TYO:3407) subsidiary Zoll Medical for an undisclosed amount.
Funds from the deal will be used to support the US market introduction and commercialization of the Irvine, Calif.-based company’s SuperSaturated Oxygen Therapy system designed to treat patients with acute myocardial infarction once the system wins FDA premarket approval.
TherOx said that it also recently released results from a study of its SSO2 Therapy system which confirmed the safety and effectiveness of the device in the treatment of anterior acute myocardial infarction...
Source: Mass Device - May 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Asahi Kasei Corp. TherOx Inc Zoll Medical Corp. Source Type: news
Timely Receipt of PCI in STEMI Up With Hospital Bypass Policy
TUESDAY, May 1, 2018 -- Adoption of policies allowing emergency medical services (EMS) to bypass non-percutaneous coronary intervention (PCI) capable hospitals for patients with ST-segment elevation myocardial infarction (STEMI) is associated with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2018 Category: Pharmaceuticals Source Type: news
SCAI updates consensus on length of stay for percutaneous coronary intervention
(Society for Cardiovascular Angiography and Interventions) Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary intervention (PCI) will allow for flexibility in length of stay while ensuring patient safety. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2018 Category: International Medicine & Public Health Source Type: news
Are angioplasty waiting time inequalities growing again?
This research looked at trends between 2002 and 2015 in waiting times for coronary angioplasty. Early indications suggest that socioeconomic inequality in waiting times for non-emergency coronary angioplasty within hospitals may have started rising in England since 2008. It also indicates that waiting times are 20% longer for patients living in deprived areas compared to patient from more affluent neighbourhoods. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 19, 2018 Category: Consumer Health News Source Type: news
Heavy US Burden of 30-Day Readmissions After PCI Heavy US Burden of 30-Day Readmissions After PCI
Almost 1 in 10 Americans undergoing percutaneous coronary intervention return with an unplanned readmission within 30 days, despite advances in the technology.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Asahi Intecc to begin direct sales of PCTA guidewires
Asahi Intecc said today it plans to begin direct sales of its coronary percutaneous transluminal coronary angioplasty guidewires in the US, which are currently only distributed by Abbott‘s (NYSE:ABT) vascular division.
The shift will take place on July 1, at which time Asahi’s entire portfolio of PTCA guidewires will be available directly from it, the Tustin, Calif.-based company said. All sales requests before the shift will be directed through Abbott, the company said.
Asahi said that in preparation for the direct offering, it has increased its sales, clinical, marketing and customer support teams. Represen...
Source: Mass Device - April 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Catheters Distribution Vascular Abbott Asahi Intecc Source Type: news
Abbot launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography.
The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said.
“Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT prov...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news
Abbott launches study comparing OCT to angiography in stent placement procedures
Abbott (NYSE:ABT) today announced the launch of new trial exploring long-term outcomes in patients who underwent stent implantation guided by optical coherence tomography as compared to angiography.
The first patient in the trial was enrolled by Dr. Franco Fabbiocchi at Milan, Italy’s IRCCS Centro Cardiologico, the Abbot Park, Ill.-based company said.
“Today, most of the world uses angiography for stent implantation using a two-dimensional view of the coronary artery to assess a complex three-dimensional structure. Physicians need new technology to help optimize percutaneous coronary intervention, and OCT prov...
Source: Mass Device - April 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Imaging Abbott Source Type: news
Better PCI Outcomes With Genotype-guided Antiplatelet Therapy Better PCI Outcomes With Genotype-guided Antiplatelet Therapy
The use of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI) is associated with better clinical outcomes, according to a new study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
